ADMA Biologics, Inc. (ADMA) — Fair Value Analysis

Base-case fair value (P50): $9.39 · Current price: $8.17 · Verdict: Fairly Valued

The Verdict on ADMA

Based on our comprehensive Monte Carlo simulations, ADMA BIOLOGICS INC (ADMA) is currently categorized as Fairly Valued within the Healthcare sector. The stock currently trades at $8.17, while our analysis indicates a median fair value (P50) of $9.39. This suggests a potential upside of +14.9% to the median fair value, positioning ADMA as neither significantly overvalued nor undervalued at its present trading level.

How ADMA stacks up against Healthcare

ADMA's operational and financial health is assessed as "average" relative to its Healthcare sector peers. This average quality tier plays a crucial role in its "Fairly Valued" verdict. While the current price of $8.17 sits below the median fair value of $9.39, the +14.9% difference aligns with the market efficiently pricing a company with average sector standing. This implies the market broadly reflects ADMA’s current intrinsic value given its industry position.

What this means for investors

Investors considering ADMA should note its "Fairly Valued" status, supported by a median fair value (P50) of $9.39 against its current price of $8.17. The +14.9% gap to the P50 indicates a reasonable expectation for price appreciation towards its intrinsic value over time, without suggesting a deeply discounted opportunity or significant overextension. Our Monte Carlo simulations, integral to the FairCurve methodology, provide a probabilistic range of future valuations. Sign up for FairCurve to see the full bear/bull distribution and track ADMA's fair value as new fundamentals are released.